Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Feature|Videos|July 29, 2024
Enzene Expands Into the US and Will Provide State-of-the-Art Fully Connected Continuous Manufacturing Services to Pharma and Biotech Companies
Author(s)Enzene Biosciences Ltd.
Dr Himanshu Gadgil, CEO, Enzene Biosciences Ltd., describes the rationale for expanding its services, including its patented EnzeneX™ continuous manufacturing technology platform, to emerging innovative, US-based biotech firms looking to benefit from the in-depth expertise in continuous manufacturing.
Watch the video and learn more:
- What distinguishes EnzeneX™ technology from other existing continuous processing manufacturing methods.
- Types of customers that can benefit from EnzeneX™ technology and other Enzene Biosciences Ltd. services.
- Updates pertaining to the launch of Enzene's first US-based manufacturing plant.
Related to this article
Today’s BioPharm Brief covers FDA’s final potency assurance guidance for cell and gene therapies, Lonza’s deal to acquire Merck KGaA’s US CDMO business, and Phase 2a data for Tiziana’s intranasal anti-CD3 antibody foralumab in progressive multiple sclerosis.
At AAPS PharmSci 360 2026, University of Iowa PhD candidate Siddhanth Hejmady explains how adding a payload or radiolabel to trastuzumab changes its behavior in bulk solution and at interfaces, and why developability teams should pair DLS with QCM-D.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
Teva will commercialize etanercept-ykro (Eticovo) and infliximab-abda, adding 2 TNF inhibitor biosimilars to US options for inflammatory diseases.
In the Phase 2a INFORM-MS trial, Tiziana’s nasal foralumab reduced microglial activation on PET imaging at 50 µg in non-active secondary progressive MS, while the 100-µg dose showed no significant effect.
The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
Trending on BioPharm International
1
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
2
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
3
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
4
Teva Licenses US Rights to Samsung Bioepis TNF Inhibitor Biosimilars
5